US 12,486,266 B2
Crystalline form of JAK inhibitor and application thereof
Weiwei Mao, Shanghai (CN); Wenyuan Qian, Shanghai (CN); Changqing Wei, Shanghai (CN); Liang Fang, Guangdong (CN); Liwei Mu, Guangdong (CN); and Shuhui Chen, Shanghai (CN)
Assigned to ZHUHAI UNITED LABORATORIES CO., LTD., Guangdong (CN)
Appl. No. 17/796,613
Filed by Zhuhai United Laboratories CO., LTD., Guangdong (CN)
PCT Filed Feb. 22, 2021, PCT No. PCT/CN2021/077228
§ 371(c)(1), (2) Date Jul. 29, 2022,
PCT Pub. No. WO2021/164786, PCT Pub. Date Aug. 26, 2021.
Claims priority of application No. 202010110530.7 (CN), filed on Feb. 21, 2020.
Prior Publication US 2023/0091250 A1, Mar. 23, 2023
Int. Cl. A61K 31/437 (2006.01); A61P 19/02 (2006.01); A61P 29/00 (2006.01); C07D 471/04 (2006.01)
CPC C07D 471/04 (2013.01) [A61K 31/437 (2013.01); A61P 19/02 (2018.01); A61P 29/00 (2018.01); C07B 2200/13 (2013.01)] 13 Claims
OG exemplary drawing
 
1. A crystal form A of compound of formula (I) that has an X-ray powder diffraction (XRPD) spectrum comprising characteristic diffraction peaks at the following 2θ angles: 6.91±0.20°, 12.21±0.20°, 13.69±0.20°, 19.06±0.20°, 19.86±0.20°, 20.59±0.20°, 22.06±0.20° and 27.52±0.20°:

OG Complex Work Unit Chemistry